INTRODUCTION
Long-term survival rates in Hodgkin lymphoma (HL) exceed 80%. However, there are serious longterm adverse effects of treatment, including cardiac and pulmonary complications and secondary malignancies. Patients with HL have an excessive mortality as a result of these effects. 1, 2 An individualized approach is needed to achieve optimal efficacy and still reduce the risk of overtreatment.
Many studies have shown a predictive value of [ 18 F]fluorodeoxyglucose (FDG) -positron emission tomography (PET) performed after two or three cycles of chemotherapy for HL. [3] [4] [5] [6] [7] A large number of ongoing trials are investigating the potential of response-adapted HL therapy, where the result of interim PET determines the onward course of treatment. 8 A few single-center studies have demonstrated good prognostic value even earlier during chemotherapy.
9,10 Early response prediction may have a number of advantages; treatment could be adapted earlier, thus limiting unnecessary or ineffective chemotherapy, and in the case of insufficient response, early escalation could theoretically reduce the risk of chemoresistance. 11 The purpose of this prospective, international, multicenter study was to assess the prognostic value of FDG-PET/computed tomography (CT) after one cycle of chemotherapy (PET1) in HL. A secondary aim was to assess the dynamics of FDG uptake in PET scans performed after one and two cycles of chemotherapy (PET2).
PATIENTS AND METHODS

Patients
The protocols were approved by the local ethical committees, and the study was performed according to the Helsinki Declaration. Written informed consent was obtained from all patients before the initiation of chemotherapy. All patients with newly diagnosed classical HL were eligible. The study was conducted by lymphoma centers in the United States, Italy, Poland, and Denmark. Before therapy, patients underwent FDG-PET/CT and contrastenhanced dedicated CT scans of the chest, abdomen, and pelvis (standalone or as part of PET/CT).
Treatment
Patients with early-stage disease were treated with two to four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine; days 1 and 15 of 28-day cycle) followed by radiotherapy to the initially involved lymph nodes or nodal areas or with six cycles of ABVD. Patients with advanced-stage disease were treated with six to eight cycles of ABVD, with or without consolidation radiotherapy. Five Danish patients with stage IIIB to IV disease with adverse risk factors were treated with eight cycles of BEACOPPesc (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Treatment was not changed on the basis of the early interim FDG-PET/ CT results.
PET/CT Scans
Interim FDG-PET/CT scans were performed within the last 5 days of the first (PET1) and second (PET2) chemotherapy courses, respectively. All patients were scanned after the first chemotherapy cycle. According to the local study protocols, US and Italian patients had PET2 only if PET1 was positive, whereas Polish and Danish patients were intended to undergo both PET1 and PET2. FDG-PET/CT scans were performed as whole-body scans after a 6-hour fast and approximately 60 to 90 minutes after intravenous injection of FDG. For each patient, PET/CT equipment and protocol were the same for baseline PET/CT, PET1, and PET2. Two US PET centers participated, whereas Italy, Poland, and Denmark each had one participating PET center.
Treatment Evaluation and Follow-Up
Final evaluation included FDG-PET/CT according to the response criteria for lymphoma.
12 Follow-up schedules most commonly included CT scans every 6 months for 2 years; thereafter, scans were performed less regularly or only on indication.
Image Analysis
FDG-PET images were evaluated according to the Deauville five-point scale.
13,14 Scores of 1 to 3 were considered negative, and scores of 4 to 5, positive. All FDG-PET/CT scans were read by an expert blinded to clinical outcome but with access to clinical information at baseline. All scans were subsequently read by an independent expert from another country, who was blinded to the first reader as well as all clinical information. In case of disagreement (ie, one positive and one negative result), both experts were asked to reach a consensus, having access to baseline clinical information but still without information about outcome. L.K. was first reader for US and Italian scans, B.M. for Polish scans, and M.H. for Danish scans. M.H. was second reader for US and Italian scans, A.B. for Polish scans, and L.K. for Danish scans.
Statistical Analysis
Progression-free (PFS) and overall survival (OS) were the end points. Survival according to FDG-PET/CT was depicted using Kaplan-Meier plots; proportional survival was determined using Kaplan-Meier statistics.
15 Differences between groups were analyzed by log-rank test. 16 All patients entered the analysis of the predictive value of PET1. Only patients with both PET1 and PET2 were included in the analysis to compare PET1 and PET2. The study was powered to demonstrate the 2-year PFS of PET1-negative patients with a margin (95% CIs) of less than Ϯ 5%. The study was not powered for a statistically valid comparison between the negative predictive value (NPV) of PET1 and PET2. Tests were two sided with a 5% significance level. Data analyses were performed using PASW software (version 18.0; SPSS, Chicago, IL).
17,18
RESULTS
A total of 126 patients with HL were prospectively included in this multicenter observational study. Clinical characteristics are listed in Table 1 . All 126 patients had a PET/CT scan after one cycle of chemotherapy, and 89 had PET/CT scans after both one and two cycles. Twenty-seven patients experienced a treatment failure, 20 of whom had primary refractory disease with progression during therapy or relapse within 3 months of completion of therapy, and seven of whom relapsed more than 3 months after completion of therapy. All relapses were confirmed by histology. Five patients died, all of whom were PET1 positive. For two patients who were early refractory to first-line therapy, salvage therapy failed, and these patients died. One patient died as a result of acute bleomycin toxicity after seven cycles of ABVD. Two patients died as a result of other cancers: one as a result of colon cancer (with HL in complete remission [CR] ) and one as a result of renal cell carcinoma (with HL in progression). The median follow-up period for this analysis was 29 months.
PET1 Results (all 126 patients)
PET scores are listed in Appendix Table A1 (online only). There was PET1 interpretation disagreement among readers in seven patients; after consensus readings, two scans were assessed as positive and five scans as negative. Overall, PET1 was read positive in 37 patients and negative in 89 patients. Figures 1 and 2 show PFS and OS curves for those patients. Two-year PFS was 94.1% for PET1-negative patients and 40.8% for PET1-positive patients. Of the 89 patients with negative PET1 results, all were in CR or partial remission (PR; n ϭ 3) after completion of first-line therapy. Five of these patients relapsed; three in PR at completion of therapy later relapsed at 1, 3, and 6 months, respectively, whereas two patients in CR at completion of therapy relapsed at 7 and 9 months, respectively. All five patients were in CR at the latest follow-up, after high-dose therapy with autologous stem-cell support. Of 37 PET1-positive patients, 17 patients had primary refractory disease, and five patients relapsed more than 3 months after reaching CR at completion of therapy. Fifteen PET1-positive patients were still in CR at the time of follow-up. These patients had baseline characteristics similar to those of the overall population (Appendix Table A2 , online only). Although age and frequency of B symptoms seemed higher in the 22 PET1-positive patients who experienced treatment failure than in the 15 PET1-positive patients in continued CR, none of these differences were statistically significant (Appendix Table A2 , online only). Median follow-up for these 15 patients was 22.5 months (range, 10 to 47 months), which was shorter than the median follow-up of 29 months for the full cohort. All five patients who died during the observation period were PET1 positive. Thus, both PFS and OS were highly statistically different in PET1-positive versus PET1-negative patients (P Ͻ .001 for both PFS and OS).
PET1 Versus PET2 Results (cohort of 89 patients)
The distribution of PET scores in this subgroup is listed in Appendix Table A3 (online only). Among patients scanned after both one and two cycles of chemotherapy, 2-year PFS was 98.3% for PET1-negative patients and 38.5% for PET1-positive patients; it was 90.2% for PET2-negative patients and 23.1% for PET2-positive patients (Table 2; Figs 3A and 3B). Of the 14 PET1-positive patients converting to a negative PET2, two converted from Deauville score 5 to 3, one Progression  27  21  18  20  21  26  Death  5  5  3  3  5  6 Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPPesc, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; CHL, classical Hodgkin lymphoma; CR, complete remission; IPS, International Prognostic Score; LR, lymphocyte rich; MC, mixed cellularity; NOS, not otherwise specified; NS, nodular sclerosis; PD, progressive disease; PET1, positron emission tomography after one chemotherapy cycle; PET2, positron emission tomography after two chemotherapy cycles; PFS, progression-free survival; PR, partial remission; SD, stable disease.
patient from score 5 to 2, seven patients from score 4 to 3, and four patients from score 4 to 2. All PET1-negative patients were also PET2 negative, and almost all patients had a PET2 score Յ the PET1 score. The only exception was one patient who progressed from score 4 at PET1 to score 5 at PET2 (Appendix Table A4 , online only). One patient progressed despite a negative PET1 (man age 18 years with stage IIIB disease who relapsed 3 to 4 months after completion of therapy). Table 3 Among 89 patients who underwent both PET1 and PET2, 62 patients were PET1 negative, and 27 patients were PET1 positive; 76 patients were PET2 negative, and 13 patients were PET2 positive. In the 62 PET1-negative patients, EOT status was as follows: CR in 60 patients, PR in one patient, and PD in one patient. In the 27 PET1-positive patients, EOT status was: CR in 15 patients, PR in three patients, SD in one patient, and PD in eight patients. In the 76 PET2-negative patients, EOT status was: CR in 70 patients, PR in two patients, and PD in four patients. In the 13 PET2-positive patients, EOT status was: CR in five patients, PR in two patients, SD in one patient, and PD in five patients. In this cohort, the NPV of PET1 for prediction of EOT CR was 96.8%. The PPV of PET1 for prediction of PR, SD, or PD was 44.4%. The NPV of PET2 for prediction of EOT CR was 92.1%. The PPV of PET2 for prediction of PR, SD, or PD was 61.5%. The correlations of PET1, PET2, and EOT PET/CT with subsequent PFS are shown in Appendix Figure A1 (online only).
Correlation With Other Risk Factors
In patients with advanced-stage disease, the International Prognostic Score (IPS) was prognostic as expected, but the prognostic value of PET1 was completely independent of IPS results (Appendix Fig A2,  online only) . The prognostic value of PET1 was shown both in patients with early-stage and in those with advanced-stage disease, with and without bulky disease (Appendix Figs A3 and A4, online only) . None of these factors influenced the prognostic value of PET1. Of note, the NPV of PET1 in patients with early-stage disease was 100%.
DISCUSSION
Many studies have shown a high prognostic accuracy of FDG-PET after two to three cycles of chemotherapy. [3] [4] [5] [6] [7] This finding has led to trials investigating treatment algorithms, with treatment adaptation 23 and two Italian trials for advanced disease 24, 25 ). Either way, the NPV associated with the early response assessment is crucial to avoid undertreatment.
In our study, no patient with early-stage HL and negative PET1 progressed or relapsed within the observation period, and among those with advanced-stage disease, long-term PFS for PET1-negative patients was more than 90%. The predictive value of positive PET1 was in the expected range, considering studies of FDG-PET after two cycles, with an overall 3-year PFS of 30% in the PET1-positive group of patients. 3, 6, 7 As in previous studies of PET after two cycles of chemotherapy, our study demonstrates that the prognostic value after one cycle is independent of IPS and also of clinical stage and presence of disease bulk.
4,6
Our results indicate that PET1 is an excellent method for identification of patients with a favorable prognosis. Negative PET1 seems more strongly correlated with a favorable outcome than negative PET2. In the group of patients scanned at both time points, only one PET1-negative patient versus seven PET2-negative patients progressed during the follow-up period. This observation, along with the fact that no PET1-negative patient was PET2 positive, shows that the NPV of PET is at least as high after one cycle than after two cycles of therapy. It should be noted that in a subset of the cohort, PET2 was performed only in patients with a positive PET1 scan. By selecting out some PET1-negative patients (presumably with excellent prognosis), we may have introduced a bias toward overestimation of the observed difference between the NPV of PET1 and PET2 (Table 2 ).
All patients in the study underwent PET/CT for EOT response evaluation. The excellent prognostic value of EOT PET/CT in HL was confirmed in this study. Two-year PFS was 93% for patients in CR compared with 5% for patients in PR or with SD or PD. The results of PET1 and PET2 were strongly correlated with EOT PET/CT status. PET1 had a better NPV than PET2 for prediction of EOT CR, whereas PET2 had a better positive predictive value than PET1 for prediction of EOT PR, SD, or PD.
Our results show more false-positive results for PET1 than for PET2, with both PFS events and EOT response as outcome parameters. In the cohort of patients with both PET1 and PET2, the falsenegative rate of PET1 was one (1.6%) of 62 for prediction of PFS events and two (3.2%) of 62 for prediction of EOT response. The false-negative rate of PET2 was five (6.6%) of 76 for prediction of PFS events and six (7.8%) of 76 for prediction of EOT response. There is no firm conclusion about whether PET1 or PET2 is the best tool for Abbreviations: PET1, positron emission tomography after one chemotherapy cycle; PET2, positron emission tomography after two chemotherapy cycles.
prognosis and treatment adaptation. Our results indicate that if the intention is treatment intensification for a patient not responding to ABVD, PET2 is better; however, if the intention is treatment deescalation-which can be an attractive option for both those with early-stage disease and some patients with advanced-stage disease-PET1 is better.
Preliminary results from two of the three early-stage HL trials were recently presented.
26,27 The RAPID trial accrued 602 patients with stage I to IIA HL. Of the 420 patients who were PET negative after three cycles of ABVD, 209 were randomly assigned to continue with involved-field radiotherapy, and 211 were randomly assigned to no further treatment (NFT). There were 20 PFS events in the NFT arm versus nine PFS events in the standard arm (median follow-up, 46 months). This led to a 3-percentage point lower 3-year PFS rate for the NFT arm versus the standard arm, within the predefined threshold of noninferiority (maximum 7% difference).
An interim analysis of the EORTC/GELA/FIL H10 trial was presented. In this trial, patients with stage I to II HL were randomly assigned to either standard combined-modality treatment or experimental arms with chemotherapy only for early PET2-negative patients or treatment escalation for early PET-positive patients. The preplanned interim analysis was performed after 10 (favorable) and 23 (unfavorable) events (approximately one third of events needed for final analysis) among 1,137 patients, with a median follow-up of 1.1 years. Seeing more PFS events in the experimental arm (favorable group, 9 v 1; unfavorable group, 16 v 7), a futility analysis found it unlikely that the final analysis will demonstrate noninferiority of the experimental arms without radiotherapy.
The results of the two trials seem comparable, but the conclusions are different, and this may be the result of the difference in follow-up period (46 v 13 months). However, it seems that PET after two to three cycles of ABVD does not clearly identify a group of patients with early-stage HL where radiotherapy can be omitted without loss of disease control. PET after one ABVD cycle might be a better discriminator in future studies aiming at the omission of radiotherapy in PET-negative patients.
Considering patients with advanced-stage HL, Gallamini et al 28 presented an interim analysis of the Gruppo Italiano Terapie Innovative nei Linfomi HD0607 trial where ABVD-treated, PET2-positive patients were switched to BEACOPPesc therapy, whereas PET2-negative patients continued with ABVD. The interim analysis of 187 patients was performed after a minimum follow-up of 12 months.
Twenty-two of the 27 early PET-positive patients achieved continued CR after switching to BEACOPPesc, and the early PET-positive patients had a 1-year PFS of 80.5%. 28 In available observational studies, PET2-positive patients had only an approximately 30% chance of long-term PFS with continued ABVD.
3,29-31 A recently opened trial for patients with advanced-stage HL is investigating an experimental approach where the results of PET/CT after one cycle of ABVD determine if patients continue with ABVD treatment (if PET negative) or are offered intensification to BEACOPPesc.
32
In conclusion, early in vivo treatment sensitivity determination by PET1 has excellent predictive properties in HL. To our knowledge, no tool identifies a subgroup of patients with HL with a more favorable outcome than those with a negative PET1 result. For those patients with a positive PET1, PET2 enhances the positive predictive value. Because of the higher rate of false-positive results associated with PET1, PET2 should remain the preferred choice for selecting nonresponding patients to switch to more aggressive treatment. In treatment strategies designed to select patients eligible for a treatment less intensive than what is otherwise the standard, a high NPV is required. In such clinical settings, and in the continued absence of precise pretherapeutic predictive markers, FDG-PET/CT after one cycle of chemotherapy seems to be an excellent tool for individualized and risk-adapted management of patients with HL.
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